Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD
护脑素小分子模拟物可使神经元 p-Akt 正常化,作为 AD 的新型疗法
基本信息
- 批准号:10211023
- 负责人:
- 金额:$ 181.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2024-03-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgeAgonistAlzheimer&aposs DiseaseAlzheimer&aposs disease modelAlzheimer&aposs disease patientAlzheimer&aposs disease therapeuticAmino AcidsAmyloid beta-ProteinAmyotrophic Lateral SclerosisArtificial MembranesBindingBinding ProteinsBiologicalBiological AssayBiological AvailabilityBrainCause of DeathCell Membrane PermeabilityCell surfaceCellsChemistryCholine O-AcetyltransferaseChondrocytesCiliary Neurotrophic Factor ReceptorCognitionComplexCritical PathwaysDataDementiaDevelopmentDiabetes MellitusDiseaseDockingDoseDrug KineticsEvaluationExposure toExtracellular DomainGenesGenetic TranscriptionGoalsHippocampus (Brain)HumanIL6ST geneImpaired cognitionIn VitroLeadLearningLibrariesMK801MembraneMemoryMitochondriaModelingMusN-Methyl-D-Aspartate ReceptorsN-MethylaspartateNerve DegenerationNeuronal PlasticityNeuronsOralPI3 genePathway interactionsPatientsPenetrancePeptidesPermeabilityPharmaceutical ChemistryPharmaceutical PreparationsPopulationPropertyProtein IsoformsProteinsReceptor SignalingReportingRisk FactorsSafetySeriesSignal TransductionSiteSolubilityStrokeStudy modelsTestingTherapeuticTissuesToxic effectTraumatic Brain Injuryacetylcholine transporterage relatedagedanalogapolipoprotein E-3apolipoprotein E-4basebrain tissuecerebrovasculardata modelingdesignefficacy testinghigh throughput screeninghumaninimprovedin silicoin vivolead candidatelead optimizationmimeticsmouse modelneuron lossneuroprotectionneurotoxicitynovel strategiesnovel therapeutic interventionnovel therapeuticspeptidomimeticsphosphoproteomicspostsynapticpre-clinicalpreclinical developmentpreventreceptorresponsescreeningsimulationsmall moleculetherapeutic development
项目摘要
PROJECT SUMMARY/ABSTRACT
Our recent discovery of orally brain permeable small molecules that mimic the bioactivity of Humanin (HN)
peptide to enhance and normalize neuronal phospho-Akt (p-Akt) levels provides a unique opportunity for
evaluating this new approach in Alzheimer's disease (AD). In this proposal, we will direct our efforts to
optimize this new class of agents, focusing on screening additional hits, enhancing their potency, drug-like
properties, solubility, oral brain permeability and efficacy in an AD model towards development of this novel
therapeutic approach for AD. We will also use modeling to identify HN based peptidomimetics for testing. Our
data show that these small molecule HN mimetics, like HN, can suppress neuronal death through its activation
of the gp130 receptor and signaling via the PI3/Akt pathway and provide neuroprotection for primary
hippocampal neurons against N-methyl D-aspartate (NMDA) and Aβ-induced neurotoxicity. HN is a naturally
occurring mitochondrial-derived brain peptide that decreases with age and may act as a neuroprotective factor
against AD-relevant neurotoxicity. Treatment of hippocampal neurons with our HN mimetic compound 2
resulted in an increase in p-Akt, and this correlated to its observed neuroprotective effects. In AD patients, a
significant decrease in p-Akt has been reported. Similarly, in aged apolipoprotein E4 (ApoE4) mice, there is a
significant decrease in p-Akt in the brain relative to age-matched ApoE3 mice suggesting that PI3/Akt signaling
is affected by ApoE4, a risk factor in AD. Activation of PI3/Akt signaling can transcriptionally modulate genes
related to memory such as choline acetyltransferase (ChAT) and vesicular acetylcholine transporter (VAChT)
and may also regulate postsynaptic proteins involved in neuroplasticity. AD is the most prevalent age-related
dementia, currently afflicting more than 5.4 million people in the US. Given the urgent need for new
therapeutic approaches for AD, these HN mimetics could provide promising lead candidates for therapeutic
development. In Aim 1, we plan to evaluate small molecule HN mimetics and peptidomimetics for activation of
gp130 and normalization of p-Akt along with their neuroprotection against Aβ and NMDA induced neurotoxicity.
In Aim 2, we would conduct a design and synthesis campaign using current SAR and new docking/modeling
data to identify small mimetics, peptides and peptidomimetics. We will optimize potency, drug-like properties,
solubility and oral brain bioavailability for efficacy testing. The best analogs/peptidomimetics from Aims 1 and 2
will undergo in vitro ADMET profiling and pharmacokinetic (PK) studies, along with phosphoproteomics
analyses, in Aim 3 to prioritize the optimal compounds for in vivo efficacy testing in the ApoE4(TR):5XFAD
murine model of AD as part of Aim 4. The goal is to identify orally available HN-mimetics that
enhance/normalize brain p-Akt levels and improve cognition. Like HN itself, they could also have broader
therapeutic applications in traumatic brain injury (TBI), stroke, Aβ-induced cerebrovascular dementia,
amyotrophic lateral sclerosis (ALS) and could lead to a new class of preclinical candidates for AD.
项目总结/摘要
我们最近发现了模拟Humanin(HN)生物活性的口服脑渗透性小分子
肽增强和正常化神经元磷酸化Akt(p-Akt)水平提供了一个独特的机会,
评估这种治疗阿尔茨海默病(AD)的新方法。在本建议中,我们将努力
优化这类新的药物,重点是筛选额外的命中,提高其效力,药物样
性质、溶解度、口服脑渗透性和在AD模型中的功效,以开发这种新的
AD的治疗方法。我们还将使用建模来鉴定用于测试的基于HN的肽模拟物。我们
数据显示,这些小分子HN模拟物,如HN,可以通过其活化抑制神经元死亡,
gp 130受体和信号转导通过PI 3/Akt途径,并提供神经保护的主要
海马神经元对N-甲基-D-天冬氨酸(NMDA)和Aβ诱导的神经毒性的保护作用。HN是一个自然
一种脑源性脑肽,随年龄增长而减少,可作为一种神经保护因子
抗AD相关神经毒性。用我们的HN模拟化合物2处理海马神经元
导致p-Akt增加,这与其观察到的神经保护作用相关。在AD患者中,
已经报道了p-Akt显著降低。同样,在老年载脂蛋白E4(ApoE 4)小鼠中,
相对于年龄匹配的ApoE 3小鼠,脑中p-Akt显著降低,表明PI 3/Akt信号传导
受AD风险因子ApoE 4影响。PI 3/Akt信号通路的激活可以转录调节基因
与记忆相关的如胆碱乙酰转移酶(ChAT)和囊泡乙酰胆碱转运蛋白(VAChT)
并且还可以调节涉及神经可塑性的突触后蛋白。AD是最常见的与年龄相关的
痴呆症,目前在美国有超过540万人受到影响。鉴于迫切需要新的
对于AD的治疗方法,这些HN模拟物可以提供有希望的用于治疗AD的先导候选物。
发展在目标1中,我们计划评估小分子HN模拟物和肽模拟物用于激活
gp 130和p-Akt沿着正常化以及它们对Aβ和NMDA诱导的神经毒性的神经保护作用。
在目标2中,我们将使用当前的SAR和新的对接/建模进行设计和综合活动
用于鉴定小模拟物、肽和肽模拟物的数据。我们将优化药效,药物性质,
溶解度和口服脑生物利用度用于功效测试。来自目标1和2的最佳类似物/肽模拟物
将进行体外ADMET分析和药代动力学(PK)研究,并沿着进行磷酸蛋白质组学研究
分析,在目标3中优先考虑用于ApoE 4(TR):5XFAD体内疗效试验的最佳化合物
AD的鼠模型作为目标4的一部分。目标是鉴定口服可利用的HN-模拟物,
增强/正常化脑p-Akt水平并改善认知。就像HN本身一样,他们也可以拥有更广泛的
在创伤性脑损伤(TBI)、中风、Aβ诱导的脑血管痴呆、
肌萎缩侧索硬化症(ALS),并可能导致一类新的临床前候选人的AD。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Varghese John其他文献
Varghese John的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Varghese John', 18)}}的其他基金
Evaluating the p-Tau inhibition and neuroprotective effects of sAPPalpha using brain permeable small molecules
使用脑通透性小分子评估 sAPPalpha 的 p-Tau 抑制和神经保护作用
- 批准号:
10522638 - 财政年份:2022
- 资助金额:
$ 181.71万 - 项目类别:
Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels
筛选降低细胞内 α-突触核蛋白水平的化合物
- 批准号:
10218979 - 财政年份:2021
- 资助金额:
$ 181.71万 - 项目类别:
Small molecule mimetics of Humanin that normalize neuronal p-Akt as novel therapeutics for AD
护脑素小分子模拟物可使神经元 p-Akt 正常化,作为 AD 的新型疗法
- 批准号:
10810521 - 财政年份:2021
- 资助金额:
$ 181.71万 - 项目类别:
Screening for enhancers of secreted clusterin (sCLU) and evaluation in AD models
分泌型凝聚素 (sCLU) 增强子的筛选和 AD 模型的评估
- 批准号:
10195566 - 财政年份:2021
- 资助金额:
$ 181.71万 - 项目类别:
Screening for Compounds that Lower Intracellular Alpha-Synuclein Levels
筛选降低细胞内 α-突触核蛋白水平的化合物
- 批准号:
10524695 - 财政年份:2021
- 资助金额:
$ 181.71万 - 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
- 批准号:
9914435 - 财政年份:2019
- 资助金额:
$ 181.71万 - 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
- 批准号:
8988211 - 财政年份:2015
- 资助金额:
$ 181.71万 - 项目类别:
ApoE4-targeted therapeutics that normalize SirT1
使 SirT1 正常化的 ApoE4 靶向疗法
- 批准号:
9231359 - 财政年份:2015
- 资助金额:
$ 181.71万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 181.71万 - 项目类别:
Research Grant